Welcome To The Mannkind HUB On AGORACOM

Edit this title from the Fast Facts Section

Free
Message: Michael Higgins on Biotech Names with Major Market Potential

Nothing mentioned about the superior response time, fewer hypo incedents and the fact the FDA engouraged MannKind to include Type 2 in their trials. The difference between monomeric insuline and hexomeric...etc.

Yet another superior research example by the writer.

How is everyone spending the last day on Earth?

Swing

Share
New Message
Please login to post a reply